Back to search results

IVS3 for Upper Limb Motor Recovery After Stroke

This study is testing a device called IVS3 to help people who have had a stroke recover movement in their arm. The IVS3 device uses a mirrored image of your healthy arm's movements to encourage your affected arm to move. We want to see if using the IVS3 device is practical and comfortable for outpatients with chronic stroke. To join, you need to be at least 18 years old, speak English, and have had a stroke at least six months ago with moderate arm weakness. We are looking to enroll 25 participants. Success in this study will be measured by how many sessions you attend and if there are any serious side effects.

Study design
This is an open-label study, meaning you and the researchers will know which treatment you are receiving. It will involve about 25 participants.
What's involved
You would attend 12 treatment sessions over 4-6 weeks. Each session involves 30 minutes with the IVS3 device and 15 minutes of conventional treatment.
Compensation
Not stated in the trial record.
Follow-up
Your progress will be monitored during the 12 treatment sessions over 4-6 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06483230

Implementation of IVS3 for Upper Limb Motor Recovery

Recruiting
NAAges 18+InterventionalTreatment
Weill Medical College of Cornell University
~25 participants
Updated 2026-09-16 on ClinicalTrials.gov
What's tested:Intensive Visual Stimulation Device

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Mean number of sessions attended
Measured over 12 treatment sessions over 4-6 weeks.
+1 more outcome measured

Conditions

Neglect, Hemispatial
Stroke, Cardiovascular
Mirror Movement
Motor Activity

Explore related trials

Stroke

NCT06483230

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Weill Cornell Medicine, 525 E. 68th St, Baker Pavilion, F-2106

    New York, New Yorkno site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Joan Stilling, MD,MS · PRINCIPAL_INVESTIGATOR · Weill Medical College of Cornell University

Who to contact

Christian Ponce Garcia, BS
[email protected]
(212) 746-1509
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Mean number of sessions attended12 treatment sessions over 4-6 weeks.

    The primary outcome measure is defined as the mean number of sessions attended of the planned twelve visits. Min 0, Max 12.

  • Number of serious adverse events12 treatment sessions over 4-6 weeks.

    The primary outcome for safety is defined as the number of serious adverse events that occur while using the IVS3 device.